ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 135 filers reported holding ROYALTY PHARMA PLC in Q3 2020. The put-call ratio across all filers is 1.34 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,917,305 | +15.5% | 70,645 | +30.9% | 0.00% | 0.0% |
| Q2 2023 | $1,659,591 | +13.1% | 53,988 | +32.6% | 0.00% | 0.0% |
| Q1 2023 | $1,467,142 | -11.2% | 40,720 | -2.6% | 0.00% | 0.0% |
| Q4 2022 | $1,652,133 | +57.5% | 41,805 | +60.2% | 0.00% | 0.0% |
| Q3 2022 | $1,049,000 | -81.4% | 26,103 | -80.5% | 0.00% | -66.7% |
| Q2 2022 | $5,635,000 | +10.8% | 134,049 | +2.7% | 0.00% | +50.0% |
| Q1 2022 | $5,086,000 | -1.6% | 130,571 | +0.6% | 0.00% | 0.0% |
| Q4 2021 | $5,171,000 | +1034.0% | 129,780 | +929.2% | 0.00% | – |
| Q3 2021 | $456,000 | -97.3% | 12,610 | -97.0% | 0.00% | -100.0% |
| Q2 2021 | $16,993,000 | -65.2% | 414,553 | -63.0% | 0.01% | -70.0% |
| Q1 2021 | $48,877,000 | -12.7% | 1,120,505 | +0.2% | 0.02% | -16.7% |
| Q4 2020 | $55,966,000 | +11.7% | 1,118,204 | -6.1% | 0.02% | 0.0% |
| Q3 2020 | $50,123,000 | -3.0% | 1,191,422 | -0.7% | 0.02% | -11.1% |
| Q2 2020 | $51,684,000 | – | 1,200,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $338,436,000 | 92.73% |
| Vantage Consulting Group Inc | 21,477,282 | $1,074,938,000 | 87.53% |
| Memorial Sloan Kettering Cancer Center | 3,565,887 | $178,473,000 | 75.56% |
| HARVARD MANAGEMENT CO INC | 14,690,780 | $735,274,000 | 39.88% |
| ROBERT WOOD JOHNSON FOUNDATION | 3,958,498 | $1,981,228,000 | 21.69% |
| Brown University | 381,759 | $19,107,000 | 13.82% |
| Overbrook Management Corp | 778,511 | $38,964,000 | 9.50% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 38,714,280 | $1,937,650,000 | 4.22% |
| Lagoda Investment Management, L.P. | 96,885 | $4,849,000 | 2.61% |
| HealthCor Management, L.P. | 1,339,530 | $67,043,000 | 2.58% |